[1] Siegel RL, Miller KD, Jemal A.Cancer statistics,2019[J]. CA: A Cancer Journal for Clinicians, 2019, 69(1): 7-34. [2] Esteban E, Majem M, Martinez AM, et al.Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study[J]. Cancer Epidemiology, 2015, 39(3): 291-297. [3] Zhong WZ, Wang Q, Mao WM, et al.Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study[J]. The Lancet Oncology, 2018, 19(1): 139-148. [4] Wu YL, Cheng Y, Zhou X, et al.Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial[J]. The Lancet Oncology, 2017, 18(11): 1454-1466. [5] Li HX, Wang HJ.Research advances of EGFR-TKI drugs in advanced NSCLC[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2019, 36(2): 245-250. [6] Scott LJ.Osimertinib as first-line therapy in advanced NSCLC: a profile of its use[J]. Drugs & Therapy Perspectives, 2018, 34(8): 351-357 [7] NCCN. Clinical practice guidelines in oncology:non-small cell lung cancer(Version 3.2019)[DB/OL].(2019-01-18)[2019-12-25]. http://www.nccn.org. [8] Wu YL, Planchard D, Lu S, et al.Pan-Asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS[J]. Annals of Oncology, 2019, 30(2): 171-210. [9] Watanabe H, Okada M, Kaji Y, et al.New response evaluation criteria in solid tumours-revised RECIST guideline (version1.1)[J]. Cancer & Chemotherapy, 2009, 36(13): 2495-2501. [10] Shuster JJ.Review: cochrane handbook for systematic reviews for interventions, version 5.1.0, published 3/2011. Julian P.T. Higgins and Sally Green, Editors[J]. Research Synthesis Methods, 2011, 2(2): 126-130. [11] Soria JC, Ohe Y, Vansteenkiste J, et al.Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. The New England Journal of Medicine, 2018, 378(2): 113-125. [12] Cho BC, Chewaskulyong B, Lee KH, et al.Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA asian subset[J]. Journal of Thoracic Oncology, 2019, 14(1): 99-106. [13] Ohe Y, Imamura F, Nogami N, et al.Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset[J]. Japanese Journal of Clinical Oncology, 2019, 49(1): 29-36. [14] Mok TS, Wu YL, Ahn MJ, et al.Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J]. The New England Journal of Medicine, 2017, 376(7): 629-640. [15] Akamatsu H, Katakami N, Okamoto I, et al.Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial[J]. Cancer Science, 2018, 109(6): 1930-1938. [16] Nie K, Zhang Z, Zhang C, et al.Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer[J]. Lung Cancer (Amsterdam, Netherlands), 2018, 121: 5-11. [17] Yan LX, Sun HM, Li Y, et al.Effect of osimertinib on T790M-postive advanced lung adenocarcinoma[J]. Journal of Chinese Practical Diagnosis and Therapy(中华实用诊断与治疗杂志), 2019, 33(4): 395-397. [18] Wang RK, Zhang ZL, Qiu B, et al.Clinical effect of osimertinib in treatment of EGFR T790M-positive non-small cell lung cancer[J]. Journal of Clinical Pulmonary Medicine(临床肺科杂志), 2019, 24(7): 1257-1260. [19] Shi Y, Li J, Zhang S, et al.Molecular epidemiology of EGFR mutations in asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology - mainland china subset analysis of the pioneer study[J]. PloS one, 2015, 10(11): e0143515. [20] Wang S, Cang S, Liu D.Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer[J]. Journal of Hematology & Oncology, 2016, 9(1): 34-34. [21] Wei HT, Li DD, Wu DX, et al.Meta-analysis of efficacy and safety of edaravone for amyotrophic lateral sclerosis[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(12): 727-733. [22] Liu GW, Yu LL, Jia HX, et al.Progress of indirect comparison and network meta-analysis method research in systematic reviews[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2014, 14(10): 1276-1280. [23] Ramalingam SS, Vansteenkiste J, Planchard D, et al.Overall survival with psimertinib in untreated, EGFR-mutated advanced NSCLC[J]. The New England Journal of Medicine, 2020, 382(1): 41-50. [24] Wu YL, Mok TSK, Han JY, et al. Overall survival (OS) from the AURA3 phase III study: osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) andprogression on a prior EGFR-tyrosine kinase inhibitor (TKI)[J]. Annals of Oncology, 2019, 30: ix158. |